Halozyme Q3 Revenue Jumps 39% on ENHANZE Royalties, Lifts 2026 Outlook
Halozyme Therapeutics reported a 39% increase in third-quarter revenue, driven by ENHANZE royalty growth, and lifted its 2026 outlook.
OverviewOutlookResult DriversCompany press release:Key DetailsAnalyst CoverageReuters Recommended ReadsFor questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.(This story was created using…